Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue (2018 - 2025)

Arcturus Therapeutics Holdings' Current Deferred Revenue history spans 8 years, with the latest figure at $8.2 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 57.74% year-over-year to $8.2 million; the TTM value through Dec 2025 reached $8.2 million, down 57.74%, while the annual FY2025 figure was $8.2 million, 57.74% down from the prior year.
  • Current Deferred Revenue reached $8.2 million in Q4 2025 per ARCT's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $71.5 million in Q1 2024 to a low of $4.7 million in Q3 2022.
  • Average Current Deferred Revenue over 5 years is $31.1 million, with a median of $27.8 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: soared 911.16% in 2021, then plummeted 91.92% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $43.5 million in 2021, then tumbled by 34.12% to $28.6 million in 2022, then surged by 56.48% to $44.8 million in 2023, then tumbled by 56.47% to $19.5 million in 2024, then plummeted by 57.74% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Current Deferred Revenue are $8.2 million (Q4 2025), $6.8 million (Q3 2025), and $11.3 million (Q2 2025).